Information on the study for Doctors

RABBIT at a Glance

Long-term monitoring of safety and efficacy of therapy with biologics, biosimilars and JAK inhibitors in patients with rheumatoid arthritis (RA) compared to therapy with conventional, synthetic DMARDs

Study design
Prospective observational study

Participating physicians
Rheumatologists in practice or special outpatient departments throughout Germany. The participation of new facilities is possible at any time! Please register via the contact form

Inclusion criteria
Patients with confirmed RA diagnosis by the rheumatologist stating the ACR criteria of 1987,
disability age >=16 years,
start of a new therapy with a biologic, biosimilar or JAK inhibitor or
restart of a therapy with a biologic, biosimilar or JAK inhibitor after at least a three-month therapy break or
start of a therapy with a conventional DMARD after failure of at least a conventional DMARD therapy.

Patients who start therapy with Remicade® have not been able to start treatment with a conventional DMARD since January 1, 2017 and patients who start a new Inflectra® therapy since January 1, 2018.03.2018 are no longer included in RABBIT.

Data collection

Questionnaires for physician and patient at the time of inclusion (at the beginning of the new therapy), after 3 and 6 months and at 6-month intervals thereafter

observation time
At least 5 years

time required for the physiciant

For the base bow approx. 15-30 minutes per patient,
for a follow-up sheet about 10 to 15 minutes per patient
Study management Pharmacoepidemiology working group of the German Rheumatism Research Center in Berlin